Holen Sie sich die Stockscreener-App
83.79
4.83%
3.86
Schlusskurs vom Vortag:
$79.93
Offen:
$81.52
24-Stunden-Volumen:
4.31M
Relative Volume:
0.78
Marktkapitalisierung:
$31.62B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
35.84
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
+7.51%
1M Leistung:
-2.90%
6M Leistung:
+40.71%
1J Leistung:
+22.86%
1-Tages-Spanne:
$79.78
$85.25
1-Wochen-Bereich:
$76.52
$80.01
52-Wochen-Spanne:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
83.79 | 31.62B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
106.62 | 184.49B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
97.22 | 124.36B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
296.69 | 113.80B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.80 | 62.03B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
93.06 | 53.64B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Overweight |
| 2026-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2026-05-12 | Eingeleitet | The Benchmark Company | Buy |
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus
Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in NovemberDexCom, Inc. - DexCom, Inc. - Investor Relations
Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider
What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance
Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga
Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street
DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research
DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research
DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView
Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com
Dexcom Inc Lobbying Profile, 2020 - OpenSecrets
Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria
DexCom, Inc. (DXCM) Options ChainYahoo Finance - Yahoo! Finance Canada
DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView
Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus
Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
DexCom Inc. Company & People | DXCM.USD - Barron's
DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada
Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa
Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com
Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alpha
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView
Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill
Here's What to Expect From DexCom’s Next Earnings Report - inkl
Here's What to Expect From DexCom’s Next Earnings Report - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dexcom Inc-Aktie (DXCM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SADIE STERN | Officer |
Oct 27 '26 |
Proposed Sale |
78.62 |
2,565 |
201,660 |
0 |
| MICHAEL BROWN | Officer |
Oct 15 '26 |
Proposed Sale |
85.48 |
1,700 |
145,316 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Oct 15 '26 |
Sale |
85.48 |
1,700 |
145,316 |
98,185 |
| Stern Sadie | EVP Chief People & Culture Off |
Sep 28 '26 |
Sale |
86.15 |
2,565 |
220,975 |
123,478 |
| SADIE STERN | Officer |
Sep 28 '26 |
Proposed Sale |
86.15 |
2,565 |
220,975 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Sale |
84.04 |
6,539 |
549,538 |
29,293 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Proposed Sale |
84.04 |
6,539 |
549,538 |
0 |
| MICHAEL BROWN | Officer |
Sep 15 '26 |
Proposed Sale |
84.04 |
1,700 |
142,868 |
0 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Proposed Sale |
84.02 |
1,550 |
130,231 |
0 |
0.62%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):